Literature DB >> 1984054

Identification of membrane anchorage domains of the HIV-1 gp160 envelope glycoprotein precursor.

D Gabuzda1, U Olshevsky, P Bertani, W A Haseltine, J Sodroski.   

Abstract

The gp41 transmembrane protein of human immunodeficiency virus type 1 (HIV-1) contains a hydrophobic membrane-spanning domain that serves to anchor the gp120-gp41 complex on the surface of infected cells and virions. To study the requirements for membrane anchorage, conservative amino acid substitutions in three residues at a time were made within this hydrophobic gp41 region. The complete gp160 precursor as well as the gp120 exterior envelope glycoprotein were exported into the supernatant of expressing cells for two mutants with amino acid substitutions in residues 687-689 and 697-699. The soluble gp160 molecules exhibited a binding ability for CD4 on the surface of SupT1 cells that was 33-36% that of the soluble gp120 glycoproteins. These results implicate residues 687-689 and 697-699 as important components of the stop-transfer signal that anchors the gp160 envelope glycoprotein precursor in the membrane. The data also suggest that characteristics in addition to hydrophobicity are required for stop-transfer signals.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 1984054

Source DB:  PubMed          Journal:  J Acquir Immune Defic Syndr (1988)        ISSN: 0894-9255


  23 in total

1.  A GxxxG-like motif within HIV-1 fusion peptide is critical to its immunosuppressant activity, structure, and interaction with the transmembrane domain of the T-cell receptor.

Authors:  Omri Faingold; Tomer Cohen; Yechiel Shai
Journal:  J Biol Chem       Date:  2012-08-07       Impact factor: 5.157

2.  Effects of deletions in the cytoplasmic domain on biological functions of human immunodeficiency virus type 1 envelope glycoproteins.

Authors:  D H Gabuzda; A Lever; E Terwilliger; J Sodroski
Journal:  J Virol       Date:  1992-06       Impact factor: 5.103

3.  Mutations within the putative membrane-spanning domain of the simian immunodeficiency virus transmembrane glycoprotein define the minimal requirements for fusion, incorporation, and infectivity.

Authors:  J T West; P B Johnston; S R Dubay; E Hunter
Journal:  J Virol       Date:  2001-10       Impact factor: 5.103

4.  Human immunodeficiency virus type 1 entry into T cells: more-rapid escape from an anti-V3 loop than from an antireceptor antibody.

Authors:  S Lu; S D Putney; H L Robinson
Journal:  J Virol       Date:  1992-04       Impact factor: 5.103

5.  gp120-independent fusion mediated by the human immunodeficiency virus type 1 gp41 envelope glycoprotein: a reassessment.

Authors:  L Marcon; J Sodroski
Journal:  J Virol       Date:  1994-03       Impact factor: 5.103

6.  Expression and characterization of glycophospholipid-anchored human immunodeficiency virus type 1 envelope glycoproteins.

Authors:  K Salzwedel; P B Johnston; S J Roberts; J W Dubay; E Hunter
Journal:  J Virol       Date:  1993-09       Impact factor: 5.103

7.  The membrane-spanning domain of gp41 plays a critical role in intracellular trafficking of the HIV envelope protein.

Authors:  Kosuke Miyauchi; A Rachael Curran; Yufei Long; Naoyuki Kondo; Aikichi Iwamoto; Donald M Engelman; Zene Matsuda
Journal:  Retrovirology       Date:  2010-11-13       Impact factor: 4.602

8.  HIV-1 gp41 and TCRalpha trans-membrane domains share a motif exploited by the HIV virus to modulate T-cell proliferation.

Authors:  Tomer Cohen; Shmuel Jaffe Cohen; Niv Antonovsky; Irun R Cohen; Yechiel Shai
Journal:  PLoS Pathog       Date:  2010-09-02       Impact factor: 6.823

9.  Role of the membrane-spanning domain of human immunodeficiency virus type 1 envelope glycoprotein in cell-cell fusion and virus infection.

Authors:  Liang Shang; Ling Yue; Eric Hunter
Journal:  J Virol       Date:  2008-03-19       Impact factor: 5.103

10.  The YXXL sequences of a transmembrane protein of bovine leukemia virus are required for viral entry and incorporation of viral envelope protein into virions.

Authors:  K Inabe; M Nishizawa; S Tajima; K Ikuta; Y Aida
Journal:  J Virol       Date:  1999-02       Impact factor: 5.103

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.